Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
16 mars 2023 08h00 HE
|
Elevar Therapeutics
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
03 août 2021 00h05 HE
|
Angion Biomedica Corp.
ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney...
Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
21 mai 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...
AB Science annonce la publication de nouveaux résultats dans la revue Glia renforçant la plausibilité du mode d’action du masitinib dans la Sclérose Latérale Amyotrophique
23 déc. 2019 02h11 HE
|
AB Science
Paris, 23 décembre 2019, 8h15 Publication de nouveaux résultats dans la revue Gliarenforçant la plausibilité du mode d’action du masitinib dansla Sclérose Latérale Amyotrophique AB Science SA (NYSE...
AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
23 déc. 2019 02h11 HE
|
AB Science
Paris, 23 December 2019, 8.15am New results published in the peer-reviewed journal Gliafurther support masitinib’s potential mode of action in ALS AB Science SA (NYSE Euronext - FR0010557264 - AB)...
AB Science fournit le résumé de la conférence web dans la mastocytose systémique indolente avec les principaux leaders d’opinion
25 nov. 2019 02h21 HE
|
AB Science
Paris, 25 novembre 2019, 8h15 Résumé de la conférence web dans la mastocytose systémique indolente avec les principaux leaders d’opinion AB Science SA (NYSE Euronext - FR0010557264 - AB) fournit le...
AB Science provides the summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis
25 nov. 2019 02h21 HE
|
AB Science
Paris, 25 November 2019, 8.15am Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis AB Science SA (NYSE Euronext - FR0010557264 - AB) is providing a summary of the live...
AB Science obtient une option de financement visant à mobiliser le crédit impôt recherche 2019 de manière anticipée
06 nov. 2019 02h23 HE
|
AB Science
Paris, 6 novembre 2019, 8h30 AB Science obtient une option de financement visant à mobiliser lecrédit impôt recherche 2019 de manière anticipée Cette option assure le financement d’AB Science...
AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit
06 nov. 2019 02h23 HE
|
AB Science
Paris, November 6, 2019, 8.30am AB Science has signed a financing agreement in order to pre-financethe 2019 research tax credit This agreement ensures company is capitalized until the end of Q2...
AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
24 oct. 2019 13h20 HE
|
AB Science
Paris, October 24, 2019, 7pm AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis Company to host live webcast on November 20, 2019...